Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Capital One Initiates Coverage On Heron Therapeutics with Overweight Rating, Announces Price Target of $6

Author: Benzinga Newsdesk | April 23, 2024 07:14am
Capital One analyst Tim Chiang initiates coverage on Heron Therapeutics (NASDAQ:HRTX) with a Overweight rating and announces Price Target of $6.

Posted In: HRTX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist